1. Portopulmonary Hypertension Associated with Congenital Absence of the Portal Vein Treated with Bosentan
- Author
-
Tomoko Hino, Yoji Neishi, Hiroyuki Okura, Nozomi Wada, Nozomi Watanabe, Takahiro Kawamoto, Kiyoshi Yoshida, Noriko Okahashi, Akihiro Hayashida, and Kikuko Obase
- Subjects
Male ,medicine.medical_specialty ,Hypertension, Pulmonary ,medicine.medical_treatment ,Portal venous pressure ,Portal vein ,Liver transplantation ,Internal medicine ,Hypertension, Portal ,Internal Medicine ,medicine ,Humans ,Developmental anomaly ,Child ,Antihypertensive Agents ,Sulfonamides ,Portopulmonary hypertension ,Portal Vein ,business.industry ,Bosentan ,General Medicine ,medicine.disease ,Pulmonary hypertension ,Treatment Outcome ,Cardiology ,Portal hypertension ,business ,medicine.drug - Abstract
Portopulmonary hypertension (PPHTN) is pulmonary arterial hypertension (PAH) associated with portal hypertension. It is a common condition among liver transplantation candidates; however, its association with congenital absence of the portal vein (CAPV) has not yet been established. CAPV is a very rare developmental anomaly, which is usually accompanied by abnormal mesenteric drainage that bypasses the liver. Here, we report a rare case of severe PPHTN secondary to CAPV.
- Published
- 2009
- Full Text
- View/download PDF